This is the new blood analysis technology with artificial intelligence to detect liver cancer

Una nueva tecnologia de blood analysis with artificial intelligence to successfully detect lung cancer has detected more than 80% of liver cancers in a study conducted with 724 people. This innovative system was developed by researchers at the Johns Hopkins Kimmel Oncology Center, in the United States. The blood analysis, called DELFI, detects changes in the DNA fragmentation of cancer cells that are released in the blood stream, known as cell-free DNA (cfDNA).

In the most recent studio, The researchers used DELFI technology in blood samples of 724 individuals from the United States, the European Union and Hong Kong to detect hepatocellular cancer, which is a type of liver cancer. Piensan que es el primer análisis de fragmentación de todo el genoma validated independently in two high risk populations and in different racial and ethnic groups with different causas asociados a sus cánceres de hígado, cuyos results se publican en la magazine ‘Cancer Discovery’ y en la Conferencia Especial de la Asociación Americana para la Investigación del Cáncer: Prevention of precision, early detection and interception of cancer.

400 millones de personas tienen un mayor riesgo de desarrollar CHC

Lo que se estima es que 400 million people in the whole world have a greater risk of developing CHC due to cirrhosis due to chronic liver diseases, donde se include la hepatitis viral crónica or la enfermedad del hígado fato no alcohólico, según un análisis mundial de la carga de la enfermedad hepatica. “El augmento de la detection precoz del cáncer de hígado could save lives, but screening tests available at the moment are underutilized and pass many cancers,” explained doctor Victor Velculescu, professor of oncology and codirector of the Genetic and Epigenetic Program of Cáncer en el Centro Oncológico Johns Hopkins Kimmel, que codirigió el estudio con Zachariah Foda, becario de gastroenterólía; Akshaya Annapragada, student, and Amy Kim, assistant professor of medicine at the Facultad de Medicina de la Universidad Johns Hopkins.

Of the 724 plasma samples that have been studied, 501 se recogieron en Estados Unidos y la UE donde incluederon muestras de 75 personas con CHC para entrenar y validar el modelo de aprendizaje automático, and tipo de inteligencia artificial en el que se utilización datos y algoritos para mejorar la precisión, explains Foda. For their part, another 223 plasma samples from Hong Kong individuals were analyzed for validation and samples from 90 persons with CHC, 66 with the hepatitis B virus, 35 with hepatic cirrhosis related to VHB and 32 persons without factores de riesgo underlying.

Technology DELFI

The DELFI technology uses blood analysis to measure the way in which DNA is packed into the nucleus of a cell, it is studied the size and quantity of DNA free from cells in the circulation of different regions of the genome.

Las célús sanas empaquetan el ADN como si fuera una maleta bien organizada donde las diferentes regions del genoma se colocan en varios compartimentos. Los núcleos de las célula cancerousosas, por el contrario, son como unas metas más bien disorganizadas con elements de todo el genoma arrojados al azarjados. When las célula cancerosas mueren, liberan fragmentos de ADN de forma caótica en el torrente sanguine.

Lo que hace DELFI es identify the presence of cancer analyzing millions of fragments of cfDNA buscando patrones abnormales, including the size and quantity of ADN in different genomic regions. The DELFI method only requires a sequence of low coverage, something that allows this technology to be profitable in a screening environment, according to researchers.

El último studio

In the last studio, los investigadores made the test in fragments of cfDNA isolated from plasma samples y analisaron los patterns de fragmentation de cada muestra para desarrollar una puntuación DELFI. Para los individuos sin cáncer with viral hepatitis or cirrhosis, the scores were poor (the median DELFI score was 0.078 and 0.080, respectively), although the median was 5 to 10 times higher for the 75 patients with CHC in the muestras de EE.UU./E.UU., con puntuaciones altas observadas en todos los estadios del cáncer, including la enfermedad en su fase inicial.

La prueba also detectó cambios de fragmentation en el contenido and the packaging of cancer genomes, including regions of the genome associated with the specific activity of the liver.

“Puede duplicar el número de casos de cáncer de hígado detectedados”

“Currently, Menos del 20% de la población de alto riesgo se somete a pruebas de detección del cáncer de hígado deboto a la accesibilidade y al rendido subóptimo de las pruebas. This new blood analysis can double the number of cases of liver cancer detected compared to the standard blood analysis available, and increase the early detection of cancer,” explains Kim, co-author of the study.

Leave a Comment

Your email address will not be published. Required fields are marked *